Trial Profile
Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Aug 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July February 2020 ).
- 03 Feb 2020 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 03 Feb 2020 Planned primary completion date changed from 1 May 2019 to 1 May 2020.